<DOC>
	<DOCNO>NCT01829971</DOCNO>
	<brief_summary>This study evaluate safety MRX34 patient primary liver cancer select solid tumor hematologic malignancy . The drug give intravenously , 5 day row two week .</brief_summary>
	<brief_title>A Multicenter Phase I Study MRX34 , MicroRNA miR-RX34 Liposomal Injection</brief_title>
	<detailed_description>This Phase I , open-label , multicenter , dose-escalation study investigate safety , Pharmacokinetics Pharmacodynamics micro ribonucleic acid ( microRNA ) MRX34 , patient unresectable primary liver cancer advance metastatic cancer without liver involvement hematologic malignancy . MRX34 administer daily x 5 2 week ( total 21 day ) 3 cycle follow no-treatment observation period .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Aged ≥ 18 year 2 . Patients histologically confirm viral related hepatocellular , SCLC , noncutaneous/ nonuveal melanoma , ovarian , TNBC , Sarcoma , Bladder RCC . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 4 . Acceptable liver function : Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; patient hepatocellular carcinoma , total bilirubin ≤ 3 mg/dL ( i.e . ChildPugh Score bilirubin great 2 ) . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase ( ALP ) ≤ 5 x ULN . 5 . Acceptable renal function : • Serum creatinine ≤ 1.5 time ULN , calculate creatinine clearance ≥ 60 mL/min/1.73 m2 patient creatinine level 1.5 time institutional normal 6 . Acceptable hematological status : Absolute Neutrophil Count ( ANC ) ≥ 1500 cells/mm3 Platelet count ≥ 100,000 plts/mm3 ( without transfusion ) ; ≥ 75,000 plts/mm3 patient hepatocellular carcinoma . For hematologic malignancy patient blood count cite apply Hemoglobin ≥ 9 g/dL For hematologic malignancy patient , blood count value cite apply . 7 . Prothrombin time ( PT ) International Normalized Ratio ( INR ) ≤ 1.25 x ULN ; patient hepatocellular carcinoma , INR &lt; 1.7 prothrombin time ( PT ) &lt; 4 second ULN ( i.e . ChildPugh Score great 1 coagulation parameter ) ; patient hepatocellular carcinoma , serum albumin &gt; 2.8 g/dL ( i.e . ChildPugh Score albumin great 2 ) . For hematologic malignancy patient , coagulation albumin status cite apply 8 . For patient hepatocellular carcinoma , ChildPugh Class A ( score 56 ) disease . Score hepatic encephalopathy must 1 ; score ascites must great 2 clinically irrelevant ; determination ChildPugh Class . 1 . Myocardial infarction within past 6 month , unstable and/or symptomatic arrhythmia , evidence ischemia ECG . 2 . Active , uncontrolled bacterial , viral , fungal infection require systemic therapy . 3 . Pregnant nursing woman . 4 . Known infection human immunodeficiency virus ( HIV ) . 5 . Serious nonmalignant disease ( e.g. , hydronephrosis , liver failure , heart failure , condition ) could compromise protocol objective opinion investigator and/or sponsor . 6 . Patients recent history hemorrhage patient predisposed hemorrhage due coagulopathies structural anomaly . 7 . Patients require treatment therapeutic dos coumadintype anticoagulant ( maximum daily dose 1mg allow port line patency permit ) . 8 . Patients cirrhosis class ChildPugh B C. 9 . Patients central nervous system ( CNS ) metastasis . Intrathecal chemotherapy allow patient require CNS prophylaxis therapy . 10 . Patients dexamethasone contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>microRNA</keyword>
	<keyword>Advanced cancer</keyword>
</DOC>